LitAlert ~~

    • Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of 9 randomized controlled trials.
    • Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.
    • Biosci Rep. 2020 Feb 25. pii: BSR20192226. doi: 10.1042/BSR20192226. [Epub ahead of print]
    • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
    • Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss A, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE.
    • J Clin Oncol. 2020 Feb 25:JCO1903292. doi: 10.1200/JCO.19.03292. [Epub ahead of print]
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.